Evidence map›Paper›PMID 42640535›Full record

ArticleRadiological physics and technology2026

Development of a CT/MRI-compatible anthropomorphic multimodal deformable male pelvic phantom for end-to-end quality assurance testing in MR-guided online adaptive radiotherapy.

Masato Nishitani, Hiroyuki Okamoto, Weishan Chang, Junichi Kuwahara, Masataka Ueda, Takahito Chiba, Hiroki Nakayama, Puspen Chakraborty, Koji Inaba, Tairo Kashihara and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masato NishitaniDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo, 116-8551, Japan. manishit@ncc.go.jp.ORCID http://orcid.org/0009-0001-2451-5012
Hiroyuki OkamotoDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo, 116-8551, Japan.
Weishan ChangDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo, 116-8551, Japan.
Junichi KuwaharaDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Masataka UedaDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Takahito ChibaSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroki NakayamaSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Puspen ChakrabortyDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo, 116-8551, Japan.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5- 1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5- 1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Satoshi NakamuraSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Tetsu NakaichiSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Yasunori ShutoDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Tatsuya SakasaiDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Tomonori GokaDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5- 1-1, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

Japan Agency for Medical Research and Development 25ck0106011h0001
6 · The paper itself

Abstract

Current quality assurance phantoms often lack MR signal, deformability, or real-time dosimetry capability, limiting comprehensive end-to-end evaluation for MR-guided online adaptive radiotherapy (MRgOART), including verification of deformable image registration (DIR) accuracy and the adaptive workflow within a single phantom. This study aimed to develop a CT/MRI-compatible anthropomorphic, deformable male pelvic phantom for a comprehensive end-to-end test of MRgOART. Reference CT value and MR signal intensity of the prostate, bone, and urine were obtained from a cohort of 30 prostate cancer patients who underwent treatment with a 0.35 T MR-Linac. MR images were acquired using a TRUFI (balanced steady-state free precession) sequence. Candidate materials were optimized to reproduce patient-like CT and MR signal characteristics, and their temporal stability was evaluated over 6 months. Relative electron density (rED) was validated using elemental analysis to ensure dose-calculation reliability. The phantom incorporated deformable prostate, rectum, and bladder models and allowed insertion of an ionization chamber for real-time internal dose measurement. The optimized materials reproduced CT value and MR signal intensity within the mean ± 1 standard deviation of patient reference data, providing clear image contrast without artifacts. CT values remained stable over time, while minor fluctuations in MR signal intensity remained within the range of physiological variability. Composition-based rED values showed small deviations from those derived by CT, which were deemed acceptable for the end-to-end test. The developed phantom enables realistic, multimodal, and deformable end-to-end evaluation of MRgOART, supporting accurate assessment of DIR, adaptive planning, and dose delivery with real-time dosimetry.

Indexed as

CT/MRI-compatible anthropomorphic multimodal deformable male pelvic phantomEnd-to-end testIonization chamber dosimeterMR-guided online adaptive radiotherapy

Identifiers

PMID42640535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.